⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

TYRA News

Tyra Biosciences, Inc. Common Stock

Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia